Zhongke Pengkai Capital

The name prefix 'Zhongke' strongly indicates institutional affiliation with the Chinese Academy of Sciences or a CAS-linked technology transfer platform, though the exact legal relationship is not publicly detailed. In China, 'Zhongke'-branded investment entities typically act as commercialization arms for CAS-affiliated research, translating laboratory innovations into for-profit ventures. This structure provides proprietary access to scientific pipelines that independent venture firms cannot replicate.

No publicly verifiable cross-border investments have been identified. The firm's mandate appears concentrated on domestic Chinese startups, with a geographic focus on the Shanghai and Yangtze River Delta region. Investments outside China would likely require a separate USD-denominated vehicle, which has not been disclosed.

The firm targets early-stage rounds, including seed and general venture. This suggests entry points at pre-revenue or early-revenue phases for deep-tech and advanced manufacturing companies. No later-stage growth or buyout activity has been documented.

No public record confirms co-investment activity with foreign general partners. Given the firm's likely RMB-denominated fund structure and CAS institutional moorings, cross-border co-investments would face both currency-control and technology-transfer regulatory scrutiny. Most comparable CAS-affiliated funds deploy alongside domestic Chinese LPs.

The firm's mandate appears focused on hard-technology verticals rooted in physical science and engineering, implying a de facto avoidance of consumer internet, platform marketplaces, and business-model-innovation plays that dominate generalist Chinese VC portfolios. No explicit negative sector screening has been published.